Medical technology company iCAD has received a device licence from Health Canada for its ProFound Risk version 2.0, a personalised breast cancer risk assessment solution.
Suitable for both 2D and 3D mammography, ProFound Risk leverages artificial intelligence for the delivery of precise, personalised and efficient risk assessments for each woman in the next one to two years.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It can be assessed even if they currently show no signs of breast cancer in their latest mammogram.
The technology combines various risk factors, including age, the density of the breast and subtle mammographic characteristics and enables medical professionals to customise screening and intervention plans according to each patient’s risk profile.
This approach provides a more personalised and comprehensive method for detecting and assessing breast cancer risks.
iCAD president and CEO Dana Brown said: “This regulatory approval further validates the clinical efficacy of our technology, paving the way for its use in healthcare facilities across Canada, where breast cancer accounts for approximately 25% of new cases of cancer and 13% of all cancer deaths in Canadian women.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Our technology offers the potential to address this significant unmet burden by empowering clinicians to personalise care for patients at higher risk of developing breast cancer in the next 1-2 years and ultimately improve outcomes for women.”
Based in Nashua, New Hampshire, iCAD is focused on offering advanced cancer detection and therapy solutions.
